surpass-cvot tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full trial results: https://nej.md/4qd5rLx SURPASS CVOT

By mimicking these hormones, Tirzepatide effectively reduces hunger, promotes satiety, and enhances glycemic control, making it a powerful tool for those struggling with obesity and type 2 diabetes

Patients who seek medication privately and are unable to access via the NHS may face a greater risk of potentially using an unsafe service if they do not choose a regulated provider

Singh P, Somers VK, Romero-Corral A, et al

Secondly, our study included a larger and more diverse population, comprising individuals with both T2D and obesity

The difference between normal GI adjustment and a medical concern usually comes down to severity and duration